Get the Stockscreener App
1.76
3.83%
-0.07
Pre-market:
1.76
Adc Therapeutics Sa stock is traded at $1.76, with a volume of 486.25K.
It is down -3.83% in the last 24 hours and down -10.20% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
See More
Previous Close:
$1.83
Open:
$1.85
24h Volume:
486.25K
Relative Volume:
0.58
Market Cap:
$170.17M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-0.5966
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+2.92%
1M Performance:
-10.20%
6M Performance:
-48.84%
1Y Performance:
-3.30%
1-Day Range:
$1.75
$1.87
1-Week Range:
$1.70
$1.87
52-Week Range:
$1.675
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.76 | 170.17M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - IT News Online
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
ADC Therapeutics Completes Enrollment in Pivotal ZYNLONTA Lymphoma Trial with 80% Response Rate - StockTitan
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Guggenheim Reaffirms “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Adc therapeutics sees $609,000 in stock purchases by Redmile - Investing.com South Africa
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
HC Wainwright Reiterates “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics stock plunges 36% amid Zynlonta data release (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics shares drop after trial results By Investing.com - Investing.com South Africa
ADC Therapeutics shares drop after trial results - Investing.com
Adc Therapeutics Sa Announces Positive Initial Data from Lotis-7 Clinical Trial Evaluating Zynlonta®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Teeters on Trial Data - Baystreet.ca
ADC Therapeutics SA Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA®? in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma - Marketscreener.com
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma - Nasdaq
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Quantisnow
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial - Marketscreener.com
Adc Therapeutics Sa Announces the Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating Zynlonta®? in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma - Marketscreener.com
Insider Selling: ADC Therapeutics SA (NYSE:ADCT) Major Shareholder Sells 25,352 Shares of Stock - MarketBeat
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clini - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Raised by Redmile Group LLC - MarketBeat
Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324) - Yahoo Finance
ADC Therapeutics Grants 34,900 Share Options to New Employees in Inducement Plan | ADCT Stock News - StockTitan
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):